New Jersey-based pharmaceutical company Merck and South Korea's Alteogen (KOSDAQ:196170) partnered to develop an injectable version of Keytruda, but California-based biotechnology firm Halozyme Therapeutics claims the drug infringes on its patents.
A patent dispute could threaten Merck's strategy to extend Keytruda's market dominance beyond its IV version's patent expirations. Halozyme signaled a preference for licensing agreements but did not comment on litigation, the Wall Street Journal reported Wednesday.
Merck, which filed invalidity petitions against Halozyme's patents, insists the claims are baseless. The subcutaneous Keytruda, still in clinical trials, is expected to launch by early 2026, the report said.
Halozyme and Alteogen both develop hyaluronidase enzyme-based drug delivery technologies, competing for injectable drug formulations.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.